Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798 Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics… bypharmanewsdailyDecember 20, 2019
